News
June 18, 2019

Regenstrief scientist explains how class of drugs may be related to dementia

Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show.

Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia. Anticholinergics are a common class of drug that includes some allergy medications, sleeping pills and many more common medicines.

Dr. Campbell recently received a $3.3 million grant from the National Institute on Aging to conduct the first clinical trial designed to determine if stopping these medications results in sustained improvements in cognition.

Listen to his discussion with the Caregiver Crossing hosts and his advice for people who are taking these medications.

Segment 1

Segment 2

Click here for more information on Caregiver Crossing.

  • Noll Campbell, PharmD, MS

Related News

Rachel Patzer, PhD

Supply, demand, and a growing US kidney transplant waiting list

Published in JAMA Network Open. Here is a link to the article.  Regenstrief Institute author: Rachel Patzer, PhD, MPH 

Jiang Bian, PhD

Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy

Published in Journal of the American College of Cardiology (JACC) CardioOncology. Here is a link to the article.  Regenstrief

Shaun Grannis, M.D., M.S.

Study reveals gaps in flu treatment for high-risk adults

INDIANAPOLIS – A multi-state study reveals that many high-risk adults diagnosed with influenza (flu) in emergency departments and urgent

Michael Weiner, MD, MPH

Regenstrief Institute researcher departs after more than two decades of service 

After more than two decades of impactful work in Indiana, Michael Weiner, M.D., MPH, is departing Regenstrief Institute, Indiana